Thomas Wessel - Net Worth and Insider Trading
Thomas Wessel Net Worth
The estimated net worth of Thomas Wessel is at least $19 dollars as of 2024-11-08. Thomas Wessel is the Chief Medical Officer of Salarius Pharmaceuticals Inc and owns about 11 shares of Salarius Pharmaceuticals Inc (SLRX) stock worth over $16. Thomas Wessel is also the Chief Medical Officer of Acorda Therapeutics Inc and owns about 208 shares of Acorda Therapeutics Inc (ACORQ) stock worth over $3. Details can be seen in Thomas Wessel's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Thomas Wessel has not made any transactions after 2016-03-14 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Thomas Wessel
Thomas Wessel Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Thomas Wessel owns 3 companies in total, including Relmada Therapeutics Inc (RLMD) , Salarius Pharmaceuticals Inc (SLRX) , and Acorda Therapeutics Inc (ACORQ) .
Click here to see the complete history of Thomas Wessel’s form 4 insider trades.
Insider Ownership Summary of Thomas Wessel
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| RLMD | Relmada Therapeutics Inc | 2020-03-09 | EVP & Head of R&D |
| SLRX | Salarius Pharmaceuticals Inc | 2016-03-14 | Chief Medical Officer |
| ACORQ | Acorda Therapeutics Inc | 2009-02-11 | Chief Medical Officer |
Thomas Wessel Latest Holdings Summary
Thomas Wessel currently owns a total of 2 stocks. Among these stocks, Thomas Wessel owns 11 shares of Salarius Pharmaceuticals Inc (SLRX) as of March 14, 2016, with a value of $16 and a weighting of 85.2%. Thomas Wessel also owns 208 shares of Acorda Therapeutics Inc (ACORQ) as of February 11, 2009, with a value of $3 and a weighting of 14.8%.
Latest Holdings of Thomas Wessel
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| SLRX | Salarius Pharmaceuticals Inc | 2016-03-14 | 11 | 1.47 | 16 |
| ACORQ | Acorda Therapeutics Inc | 2009-02-11 | 208 | 0.01 | 3 |
Holding Weightings of Thomas Wessel
Thomas Wessel Form 4 Trading Tracker
According to the SEC Form 4 filings, Thomas Wessel has made a total of 0 transactions in Salarius Pharmaceuticals Inc (SLRX) over the past 5 years. The most-recent trade in Salarius Pharmaceuticals Inc is the acquisition of 4 shares on March 14, 2016, which cost Thomas Wessel around $158,800.
According to the SEC Form 4 filings, Thomas Wessel has made a total of 0 transactions in Acorda Therapeutics Inc (ACORQ) over the past 5 years. The most-recent trade in Acorda Therapeutics Inc is the sale of 0 shares on February 11, 2009, which brought Thomas Wessel around $0.
Insider Trading History of Thomas Wessel
- 1
Thomas Wessel Trading Performance
GuruFocus tracks the stock performance after each of Thomas Wessel's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Thomas Wessel is 9.05%. GuruFocus also compares Thomas Wessel's trading performance to market benchmark return within the same time period. The performance of stocks bought by Thomas Wessel within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Thomas Wessel's insider trading performs compared to the benchmark.
Performance of Thomas Wessel
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 24.25 | | | | | |
| Relative Return to S&P 500(%) | 21.12 | | | | | |
Thomas Wessel Ownership Network
Ownership Network List of Thomas Wessel
Ownership Network Relation of Thomas Wessel
Thomas Wessel Owned Company Details
What does Relmada Therapeutics Inc do?
Who are the key executives at Relmada Therapeutics Inc?
Thomas Wessel is the EVP & Head of R&D of Relmada Therapeutics Inc. Other key executives at Relmada Therapeutics Inc include director & Chief Executive Officer Sergio Traversa , Chief Financial Officer Chuck Ence , and Chief Medical Officer Cedric O'gorman .
Relmada Therapeutics Inc (RLMD) Insider Trades Summary
Over the past 18 months, Thomas Wessel made no insider transaction in Relmada Therapeutics Inc (RLMD). Other recent insider transactions involving Relmada Therapeutics Inc (RLMD) include a net purchase of 240,000 shares made by Sergio Traversa , a net purchase of 86,107 shares made by Maged Shenouda , and a net purchase of 38,970 shares made by Chuck Ence .
In summary, during the past 3 months, insiders sold 0 shares of Relmada Therapeutics Inc (RLMD) in total and bought 231,432 shares, with a net purchase of 231,432 shares. During the past 18 months, 0 shares of Relmada Therapeutics Inc (RLMD) were sold and 413,077 shares were bought by its insiders, resulting in a net purchase of 413,077 shares.
Relmada Therapeutics Inc (RLMD)'s detailed insider trading history can be found in Insider Trading Tracker table.
Relmada Therapeutics Inc Insider Transactions
Thomas Wessel Mailing Address
Above is the net worth, insider trading, and ownership report for Thomas Wessel. You might contact Thomas Wessel via mailing address: 15 Skyline Drive, Hawthorne Ny 10532.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
